Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study

English version České info

Background:
A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009–2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1).

Methods and Findings:
Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study patients meeting the European ILI case definition with onset of symptoms >14 days after the start of national pandemic vaccination campaigns. We compared pH1N1 cases to influenza laboratory-negative controls. A valid vaccination corresponded to >14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis excluding individuals with missing values and a multiple multivariate imputation to estimate missing values. The multivariate imputation (n = 2902) adjusted pandemic VE (PIVE) estimates were 71.9% (95% confidence interval [CI] 45.6–85.5) overall; 78.4% (95% CI 54.4–89.8) in patients <65 years; and 72.9% (95% CI 39.8–87.8) in individuals without chronic disease. The complete case (n = 1,502) adjusted PIVE were 66.0% (95% CI 23.9–84.8), 71.3% (95% CI 29.1–88.4), and 70.2% (95% CI 19.4–89.0), respectively. The adjusted PIVE was 66.0% (95% CI −69.9 to 93.2) if vaccinated 8–14 days before ILI onset. The adjusted 2009–2010 seasonal influenza VE was 9.9% (95% CI −65.2 to 50.9).

Conclusions:
Our results suggest good protection of the pandemic monovalent vaccine against medically attended pH1N1 and no effect of the 2009–2010 seasonal influenza vaccine. However, the late availability of the pandemic vaccine and subsequent limited coverage with this vaccine hampered our ability to study vaccine benefits during the outbreak period. Future studies should include estimation of the effectiveness of the new trivalent vaccine in the upcoming 2010–2011 season, when vaccination will occur before the influenza season starts.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study. PLoS Med 8(1): e32767. doi:10.1371/journal.pmed.1000388
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000388

Souhrn

Zdroje

1. ClarkTW

PareekM

HoschlerK

DillonH

NicholsonKG

2009 Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361 2424 2435

2. PlennevauxE

SheldonE

BlatterM

Reeves-HocheMK

2010 Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 375 41 48

3. VajoZ

TamasF

SinkaL

JankovicsI

2010 Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial 291. Lancet 375 49 55

4. Garcia-GarciaL

Valdespino-GomezJL

Lazcano-PonceE

Jimenez-CoronaA

Higuera-IglesiasA

2009 Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 339 b3928 Available: http://www.bmj.com/cgi/content/full/339/oct06_2/b3928. Accessed 14 October 2010

5. KellyH

GrantK

2009 Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 14 Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19288. Accessed 14 October 2010

6. GargiulloP

ShayDK

KatzJ

BramleyA

NowellM

2009 Effectiveness of 2008–09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May–June 2009. MMWR Morb Mortal Wkly Rep 58 1241 1245 mm5844a5 [pii]. Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5844a5.htm Accessed 14 October 2010

7. SkowronskiDM

DeSG

CrowcroftNS

JanjuaNZ

BoulianneN

2010 Association between the 2008–09 seasonal influenza vaccine and pandemic H1N1 illness during Spring–Summer 2009: four observational studies from Canada 294. PLoS Med 7 e1000258 doi:10.1371/journal.pmed.1000258

8. ValencianoM

CiancioB

MorenA

2008 First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States 2. Euro Surveill 13 19015 Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19015. Accessed 16 May 2010

9. PitigoiD

LupulescuE

AlexandrescuV

BaetelA

SbarceaC

2009 [Efficiency of seasonal influenza vaccine in persons older than 65 in Romania. Pilot case-control study I-MOVE, 2008–2009] 301. Bacteriol Virusol Parazitol Epidemiol 54 109 116

10. SavulescuC

ValencianoM

de MateoS

LarrauriA

2010 Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network-Pilot case-control studies using different control groups, 2008–2009 season, Spain. Vaccine 28 2903 2907

11. KisslingE

ValencianoM

FalcaoJ

LarrauriA

WidgrenK

2009 “I-MOVE” towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008–9. Euro Surveill 14 19388 Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19388. Accessed 14 October 2010

12. European Centre for Disease Prevention and Control (ECDC) 2010 European Influenza Surveillance Network (EISN). Available http://www.ecdc.europa.eu/en/activities/surveillance/EISN/Pages/home.aspx Accessed 14 October 2010

13. European Commission Commission Decision 2009/363/EC of 30 April 2009 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council, OJ L 110, 1.5.208, p. 58. Available: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:110:0058:0059:EN:PDF. Accessed 14 October 2010

14. SterneJA

WhiteIR

CarlinJB

SprattM

RoystonP

2009 Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338 b2393

15. HienTT

BoniMF

BryantJE

NganTT

WolbersM

2010 Early pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysis. PLoS Med 7 e1000277 doi:10.1371/journal.pmed.1000277

16. RodriguesL

KirkwoodBR

1990 Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol 19 205 213

17. BelongiaEA

KiekeBA

DonahueJG

GreenleeRT

BalishA

2009 Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004–2005 season to the 2006–2007 season. J Infect Dis 199 159 167

18. FlemingDM

AndrewsNJ

ElllisJS

BerminghamA

SebastianpillaiP

2010 Estimating Influenza vaccine effectiveness using routinely collected laboratory data. J Epidemiol Community Health 64 1062 1067

19. KellyH

CarvilleK

GrantK

JacobyP

TranT

2009 Estimation of influenza vaccine effectiveness from routine surveillance data. PLoS One 4 e5079 doi:10.1371/journal.pone.0005079

20. SkowronskiDM

DeSG

DickinsonJ

PetricM

MakA

2009 Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006–2007. J Infect Dis 199 168 179

21. BlettnerM

SauerbreiW

SchlehoferB

ScheuchenpflugT

FriedenreichC

1999 Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28 1 9

22. JacksonML

NelsonJC

WeissNS

NeuzilKM

BarlowW

2008 Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 372 398 405

23. WichmannO

StockerP

PoggenseeG

AltmannD

WalterD

2010 Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 15 19561 Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19561. Accessed 14 October 2010

24. Puig-BarberaJ

Arnedo-PenaA

Pardo-SerranoF

Tirado-BalaguerMD

Perez-VilarS

2010 Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital based, case-control study. Vaccine 28 7460 7467

25. SimpsonCR

RitchieLD

RobertsonC

SheikhA

McMenaminJ

2010 Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol Assess 14 313 346

26. SkowronskiDM

MasaroC

KwindtTL

MakA

PetricM

2007 Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 25 2842 2851